SCHEMBL20522794

SCHEMBL20522794

O=C1CC(c2cccs2)=NN1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.53
PBRM1 Q86U86 1/20 0.53
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
ALDH1A1 P00352 4/20 0.46
GPR119 Q8TDV5 3/20 0.45
MAPT P10636 5/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
KDM4E B2RXH2 2/20 0.38
LTK P29376 1/20 0.38
CDK5 Q00535 1/20 0.38
MST1R Q04912 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8478610 0.84 GPR119 (0.56) AXLPBRM1SMN1; SMN2NPC1RAB9A
SCHEMBL31553378 0.75 PDE3B (0.44) PBRM1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL19205895 0.72 ALDH1A1 (0.44) PBRM1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL8475012 0.72 GPR119 (0.60) PBRM1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL2375581 0.69 AXL (1.00) AXLSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL16157206 0.69 PBRM1 (1.00) PBRM1GPR119PDE3BPDE3A
SCHEMBL5566954 0.68 AXL (0.69) AXLSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL6857445 0.68 AXL (0.44) AXLSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL11710676 0.68 NOTUM (0.46) PBRM1SMN1; SMN2ALDH1A1MAPTL3MBTL1
SCHEMBL6849455 0.68 AXL (0.58) AXLSMN1; SMN2ALDH1A1GPR119CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11617738-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2023-04-04 US disclosed
US-20210196684-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2021-07-01 US disclosed
US-20210196684-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2021-07-01 US disclosed
US-10980781-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2021-04-20 US disclosed
US-10980781-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2021-04-20 US disclosed
US-20200078336-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2020-03-12 US disclosed
WO-2018183587-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200078336-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE USP7, USP3, USP2 AXL 2748/4885PBRM1 2382/4885SMN1; SMN2 3552/4885
US-20210196684-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE USP7, USP3, USP2 AXL 2748/4885PBRM1 2382/4885SMN1; SMN2 3552/4885
US-10980781-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use USP7, USP3, USP2 AXL 2748/4885PBRM1 2382/4885SMN1; SMN2 3552/4885
US-11617738-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use USP7, USP3, USP2 AXL 2748/4885PBRM1 2382/4885SMN1; SMN2 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.